{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:19:08Z","timestamp":1790957948027,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Heron Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12325-020-01377-z","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T07:02:51Z","timestamp":1590217371000},"page":"3265-3277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Derek","family":"Burns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna","family":"Kula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ornelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"key":"1377_CR1","unstructured":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: antiemesis\u2014version 1.2019. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 2 Mar 2020"},{"issue":"15","key":"1377_CR2","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/cncr.30054","volume":"122","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016;122(15):2418\u201325.","journal-title":"Cancer"},{"issue":"3","key":"1377_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00520-016-3463-0","volume":"25","author":"JE Kim","year":"2017","unstructured":"Kim JE, Jang JS, Kim JW, et al. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer. 2017;25(3):801\u20139.","journal-title":"Support Care Cancer"},{"key":"1377_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, Jordan K, Green SA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2016;27:172\u20138.","journal-title":"Ann Oncol"},{"issue":"7","key":"1377_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25(7):1340\u20136.","journal-title":"Ann Oncol"},{"issue":"4","key":"1377_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/annonc\/mds541","volume":"24","author":"H Saito","year":"2013","unstructured":"Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24(4):1067\u201373.","journal-title":"Ann Oncol"},{"issue":"11","key":"1377_CR7","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1007\/s00520-015-2738-1","volume":"23","author":"B Rapoport","year":"2015","unstructured":"Rapoport B, Chua D, Poma A, et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015;23(11):3281\u20138.","journal-title":"Support Care Cancer"},{"key":"1377_CR8","doi-asserted-by":"crossref","unstructured":"Raman M, Almutairdi A, Mulesa L, et al. Parenteral nutrition and lipids. Nutrients. 2017;9(4):388.","DOI":"10.3390\/nu9040388"},{"key":"1377_CR9","unstructured":"Emend\u00ae (fosaprepitant) for injection, for intravenous use [prescribing information]. Merck & Co., Whitehouse Station, NJ. January 2019."},{"key":"1377_CR10","unstructured":"Fosaprepitant for injection, for intravenous use [prescribing information]. Teva., North Wales, PA. September 2019"},{"key":"1377_CR11","unstructured":"Cinvanti\u00ae (aprepitant) injectable emulsion, for intravenous use. Heron Therapeutics, Inc., San Diego, CA. February 2019."},{"issue":"1","key":"1377_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, et al. 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277\u201388.","journal-title":"Support Care Cancer"},{"issue":"28","key":"1377_CR13","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240\u201361.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1377_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ, et al. 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer. 2017;25(1):289\u201394.","journal-title":"Support Care Cancer"},{"key":"1377_CR15","unstructured":"ASHP and the University of Utah Drug Information Service. Small-volume parenteral solutions shortages: suggestions for management and conservation. US Food and Drug Administration website; 2017. https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/DrugShortages\/UCM582461.pdf. Accessed 2 Jan 2020."},{"key":"1377_CR16","unstructured":"US Food and Drug Administration. FDA Commissioner Scott Gottlieb, M.D., updates on some ongoing shortages related to IV fluids (2018 Jan 16). https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm592617.htm. Accessed 29 Jul 2019."},{"key":"1377_CR17","unstructured":"Cinvanti (aprepitant) Injectable Emulsion, for Intravenous (IV) Use Admixture Stability with Palonosetron and\/or Dexamethasone. Medical Information Response. Heron Therapeutics, Inc. 2018 (May 11)."},{"key":"1377_CR18","unstructured":"U.S. Pharmacopeia. United States Pharmacopeia and National Formulary (USP 42-NF 37). Pharmaceutical Compounding - Sterile Preparations. Rockville, MD: US Pharmacopeia; 2019; chap 797."},{"key":"1377_CR19","unstructured":"Centers for Disease Control and Prevention. One & Only Campaign. US Department of Health and Human Services. https:\/\/www.oneandonlycampaign.org\/. Accessed 20 Jan 2020."},{"key":"1377_CR20","unstructured":"Institute for Safe Medication Practices. ISMP safe practice guidelines for adult IV push medications: a compilation of safe practices from the ISMP Adult IV Push Safety Summit. 2015. https:\/\/www.ismp.org\/Tools\/guidelines\/IVSummitPush\/IVPushMedGuidelines.pdf. Accessed 20 Jan 2020."},{"issue":"Pt A","key":"1377_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejpb.2015.09.016","volume":"97","author":"TA Khan","year":"2015","unstructured":"Khan TA, Mahler HC, Kishore RS. Key interactions of surfactants in therapeutic protein formulations: a review. Eur J Pharm Biopharm. 2015;97(Pt A):60\u20137.","journal-title":"Eur J Pharm Biopharm"},{"issue":"8","key":"1377_CR22","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/jps.21190","volume":"97","author":"BA Kerwin","year":"2008","unstructured":"Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci. 2008;97(8):2924\u201335.","journal-title":"J Pharm Sci"},{"key":"1377_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2147\/DDDT.S155875","volume":"12","author":"T Ottoboni","year":"2018","unstructured":"Ottoboni T, Keller MR, Cravets M, et al. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a phase I, open-label, randomized, two-way crossover evaluation. Drug Des Dev Ther. 2018;12:429\u201335.","journal-title":"Drug Des Dev Ther"},{"issue":"27","key":"1377_CR24","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.2217\/fon-2018-0311","volume":"14","author":"T Ottoboni","year":"2018","unstructured":"Ottoboni T, Lauw M, Keller MR, et al. Safety of HTX-019 (IV aprepitant) and fosaprepitant in healthy subjects. Future Oncol. 2018;14(27):2849\u201359.","journal-title":"Future Oncol"},{"issue":"5","key":"1377_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/NAN.0000000000000341","volume":"42","author":"G Calcanes","year":"2019","unstructured":"Calcanes G, Vacirca JL. Safety profile of HTX-019 administered as an intravenous infusion in patients with cancer. J Infusion Nurs. 2019;42(5):1\u20134.","journal-title":"J Infusion Nurs"},{"key":"1377_CR26","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.2147\/OTT.S201609","volume":"12","author":"RM Navari","year":"2019","unstructured":"Navari RM, Mosier MC. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. Oncotargets Ther. 2019;12:3277\u201384.","journal-title":"Oncotargets Ther"},{"key":"1377_CR27","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0835","author":"TS Perry","year":"2020","unstructured":"Perry TS, Dickson N, Patton JF. Safety of antiemetic prophylaxis with HTX-019 as a 30-min infusion in patients with cancer: a retrospective study. Future Oncol. 2020. https:\/\/doi.org\/10.2217\/fon-2019-0835.","journal-title":"Future Oncol"},{"issue":"8","key":"1377_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2217\/fon-2018-0809","volume":"15","author":"T Ottoboni","year":"2019","unstructured":"Ottoboni T, Lauw M, Keller MR, et al. HTX-019 via 2-min injection or 30-min infusion in healthy subjects. Future Oncol. 2019;15(8):865\u201374.","journal-title":"Future Oncol"},{"key":"1377_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1691521","author":"RM Navari","year":"2020","unstructured":"Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Safety. 2020. https:\/\/doi.org\/10.1080\/14740338.2020.1691521.","journal-title":"Expert Opin Drug Safety"},{"issue":"3","key":"1377_CR30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12325-019-0877-3","volume":"36","author":"GD Walton","year":"2019","unstructured":"Walton GD. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Adv Ther. 2019;36(3):662\u20139.","journal-title":"Adv Ther"},{"issue":"4","key":"1377_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1200\/JOP.2015.008458","volume":"12","author":"C Balch","year":"2016","unstructured":"Balch C, Ogle JD, Senese JL. The National Practice Benchmark for Oncology: 2015 Report for 2014 Data. J Oncol Pract. 2016;12(4):437\u201375.","journal-title":"J Oncol Pract"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01377-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01377-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T23:13:03Z","timestamp":1621725183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01377-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01377-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"5 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}